THE REATA MISSION

At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better.

COMMITTED TO MAKING A POSITIVE IMPACT

Reata is focused on developing novel therapies for life threatening diseases that have few or no treatment options…
Using modern biotechnology to develop novel therapies for life threatening diseases.
Learn More

FOCUSED ON CELLULAR METABOLISM & INFLAMMATION

Nrf2 activators exhibit broad, anti-inflammatory, anti-fibrotic, and promitochondrial activity in vitro and have many potential clinical applications1-3
Focused on cellular metabolism and inflammation.
Learn More

EXTENSIVE AND PROMISING PIPELINE

Our product candidates have the potential to treat patients with high unmet medical need…
Reata Pharma has an extensive and promising pipeline
Learn More

Our Pipeline

Reata’s development programs have created a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases. Find out more here.

PIVOTAL PROGRAMS

Discovery
Preclinical
Phase 1
Phase 2
Pivotal
Alport syndrome | Bard
 
 
 
 
Friedreich's ataxia | Omav
 
 
 
 
CTD-PAH | Bard
 
 
 
 
ADPKD | Bard
 
 
 
 

Bard=bardoxolone methyl; CTD-PAH=connective tissue disease-associated pulmonary arterial hypertension; Omav=omaveloxolone; ADPKD=autosomal dominant polycystic kidney disease.

Bardoxolone methyl and omaveloxolone are investigational drugs. Safety and efficacy have not been established by any agency.

See Full Pipeline

References
  1. Chin M, Lee CY, Chuang JC, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of type 2 diabetes and obesity. Am J Physiol Renal Physiol. 2013;304(12):F1438-F1446.
  2. Tan SM, Sharma A, Stefanovic N, et al. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes. 2014;63(9):3091-3103.
  3. Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich’s ataxia models. Front Cell Neurosci. 2018;12:188.
View References